Citations 236

O2‐14‐02: THE CLINICAL SPECTRUM OF FRONTOTEMPORAL LOBAR DEGENERATION IN NORTH AMERICA: BASELINE CHARACTERISTICS OF THE FIRST 912 PARTICIPANTS FROM THE ADVANCING RESEARCH AND TREATMENT IN FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_12 | Pages: No page available

10.1016/j.jalz.2018.06.2719

O2‐14‐01: CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_12 | Pages: No page available

10.1016/j.jalz.2018.06.2718

O1‐08‐01: THE NIH‐EXAMINER IS SENSITIVE TO COGNITIVE CHANGES IN ASYMPTOMATIC AND MILDLY SYMPTOMATIC FAMILIAL FRONTOTEMPORAL DEMENTIA

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2018.06.2372

P2‐430: MR SPECTROSCOPY FROM FRONTAL LOBE AND POSTERIOR CINGULATE GYRUS IN ASYMPTOMATIC AND SYMPTOMATIC MICROTUBULE‐ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_16 | Pages: No page available

10.1016/j.jalz.2018.06.1122

P1‐433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC MAPT MUTATION CARRIERS

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2018.06.442

P1‐420: ACCELERATED NEUROCHEMICAL CHANGES PRIOR TO PHENOCONVERSION TO FRONTOTEMPORAL LOBAR DEGENERATION IN PRESYMPTOMATIC MICROTUBULE‐ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS: A LONGITUDINAL MRS STUDY

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2018.06.429

P1‐419: USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2018.06.428

P1‐281: NONLINEAR N‐SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER'S COORDINATING CENTER (NACC) DATASET

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2018.06.287

A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers

Brain | August 31, 2018 | Volume: 141 | Issue: 10 | Pages: 2895-2907

10.1093/brain/awy238 | PMID 30252044

Three VCP Mutations in Patients with Frontotemporal Dementia

Journal of Alzheimer’s Disease | August 10, 2018 | Volume: 65 | Issue: 4 | Pages: 1139-1146

10.3233/jad-180301 | PMID 30103325

Valosin-containing protein ( VCP) is involved in multiple cellular activities. Mutations in VCP lead to heterogeneous clinical presentations including inclusion body myopathy with Paget’s disease of the bone, frontotemporal dementia and amyotrophic lateral sclerosis, even in patients carrying the same mutation. We screened a cohort of 48 patients with familial frontotemporal dementia (FTD) negative for MAPT, GRN, and C9orf72 mutations for other known FTD genes by using whole exome sequencing. In addition, we carried out targeted sequencing of a cohort of 37 patients with frontotemporal lobar degeneration with Transactive response DNA-binding protein 43 (TDP-43) subtype from the Netherlands Brain bank. Two novel (p.Thr262Ser and p.Arg159Ser) and one reported (p.Met158Val) VCP mutations in three patients with a clinical diagnosis of FTD were identified, and were absence in population-match controls. All three patients presented with behavioral changes, with additional semantic deficits in one. No signs of Paget or muscle disease were observed. Pathological examination of the patient with VCP p.Arg159Ser mutation showed numerous TDP-43 immunoreactive (IR) neuronal intranuclear inclusions (NII) and dystrophic neurites (DN), while a lower number of NII and DN were observed in the patient with the VCP p.Thr262Ser mutation. Pathological findings of both patients were consistent with FTLD-TDP subtype D. Furthermore, only rare VCP-IR NII was observed in both cases. Our study expands the clinical heterogeneity of VCP mutations carriers, and indicates that other additional factors, such as genetic modifiers, may determine the clinical phenotype.